The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

Stelo CGM Launch: In August 2024, DexCom announced the commercial launch of Stelo CGM, the first over-the-counter glucose sensor in the U.S. for non-insulin using Type 2 diabetes and prediabetes ...

Keep a constant eye on your blood sugar levels and sync your results to a phone or a smart watch with a top-quality CGM. Want to track your glucose levels without the hassle of finger pricks?

The FDA cited issues with DexCom’s response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7, 2024, ...

Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...

DexCom Call and Put Volume: 30-Day Overview Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional ...